SCHEMBL10076308

SCHEMBL10076308

CCN(CC)Cc1ccc(OC)cc1

nearest known ligand 0.61

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 1/20 0.61
TSHR P16473 1/20 0.58
MAPK1 P28482 1/20 0.58
APLNR P35414 1/20 0.53
AOC3 Q16853 1/20 0.52
IDO1 P14902 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetic Acid SCHEMBL23429845 0.89 HRH3 (0.56) HRH3TSHRMAPK1APLNR
SCHEMBL12049800 0.89 APLNR (0.59) TSHRMAPK1APLNRAOC3IDO1
SCHEMBL5270803 0.89 APLNR (0.59) TSHRMAPK1APLNRAOC3IDO1
SCHEMBL22340700 0.88 TSHR (0.75) TSHRMAPK1
SCHEMBL22340500 0.88 HRH3 (0.55) HRH3TSHRMAPK1AOC3
SCHEMBL14382168 0.88 TSHR (0.51) HRH3TSHRMAPK1APLNRAOC3
SCHEMBL20871857 0.85 MAPT (0.54) TSHRMAPK1
SCHEMBL17230510 0.85 TSHR (0.49) TSHRMAPK1AOC3
SCHEMBL11453792 0.85 TAAR1 (0.52) HRH3TSHRMAPK1APLNRAOC3
SCHEMBL20871868 0.84 TSHR (0.53) HRH3TSHRMAPK1APLNRAOC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11636986-B2 Flexible, biodegradable and biocompatible supercondenser BIO-ON S.P.A. (IT) 2023-04-25 US claimed
US-20220028628-A1 FLEXIBLE, BIODEGRADABLE AND BIOCOMPATIBLE SUPERCONDENSER BIO ON S.P.A. (IT) 2022-01-27 US claimed
EP-3707132-B1 NEW METHOD FOR THE SYNTHESIS OF UNSYMMETRICAL TERTIARY AMINES UNIV PARIS SACLAY (FR) 2024-07-17 EP disclosed
US-11680250-B2 Light-driven system and methods for chemical modification of an organic substrate UNIVERSITY OF COPENHAGEN (DK) 2023-06-20 US disclosed
US-11636986-B2 Flexible, biodegradable and biocompatible supercondenser BIO-ON S.P.A. (IT) 2023-04-25 US disclosed
EP-3227292-B1 4H-PYRIDO[1,2-a]PYRIMIDIN-4-ONE COMPOUNDS ALTERITY THERAPEUTICS LTD (AU) 2022-03-09 EP disclosed
US-20220028628-A1 FLEXIBLE, BIODEGRADABLE AND BIOCOMPATIBLE SUPERCONDENSER BIO ON S.P.A. (IT) 2022-01-27 US disclosed
EP-3322802-B1 LIGHT-DRIVEN SYSTEM AND METHODS FOR CHEMICAL MODIFICATION OF AN ORGANIC SUBSTRATE UNIV COPENHAGEN (DK) 2022-01-19 EP disclosed
EP-3929198-A1 HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) 2021-12-29 EP disclosed
US-11034646-B2 Method for the synthesis of unsymmetrical tertiary amines Universite Paris-Saclay (FR) 2021-06-15 US disclosed
US-11028249-B2 Methods of synthesizing ionic liquids from primary alcohol-containing lignin compounds NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA, LLC (US) 2021-06-08 US disclosed
US-20080113989-A1 For example, N-(1-Carbamoyl-1-oxo-3-phenylpropan-2-yl)-2-(E-2-(4-(1-pyrrolidinylmethyl)phenyl)ethen-1-yl)benzamide; calcium channel blockers; cardiovascular disorders; antiarthritic agents; inhibitors of enzymes, especially cysteine proteases such as calpain and cathepsins ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2008-05-15 US disclosed
US-7276500-B2 Calcium channel blockers; cardiovascular disorders; antiarthritic agents ABBOTT GMBH & CO. KG (DE) 2007-10-02 US disclosed
US-7276500-B2 Calcium channel blockers; cardiovascular disorders; antiarthritic agents ABBOTT GMBH & CO. KG (DE) 2007-10-02 US disclosed
US-20070197508-A1 NOVEL PROCESSES FOR THE PREPARATION OF PIPERAZINYL AND DIAZAPANYL BENZAMIDE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2007-08-23 US disclosed
US-20070197508-A1 NOVEL PROCESSES FOR THE PREPARATION OF PIPERAZINYL AND DIAZAPANYL BENZAMIDE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2007-08-23 US disclosed
US-20070129351-A1 NOVEL PROCESSES FOR THE PREPARATION OF CYCLOPROPYL-AMIDE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2007-06-07 US disclosed
US-20070129351-A1 NOVEL PROCESSES FOR THE PREPARATION OF CYCLOPROPYL-AMIDE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2007-06-07 US disclosed
WO-2007053386-A2 PROCESSES FOR THE PREPARATION OF CYCLOPROPYL-AMIDE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2007-05-10 WO disclosed
WO-2007053427-A2 NOVEL PROCESSES FOR THE PREPARATION OF PIPERAZINYL AND DIAZAPANYL BENZAMIDE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2007-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197508-A1 NOVEL PROCESSES FOR THE PREPARATION OF PIPERAZINYL AND DIAZAPANYL BENZAMIDE DERIVATIVES HRH2, HRH4, HRH1 HRH3 4/4885TSHR 463/4885MAPK1 3455/4885
US-11028249-B2 Methods of synthesizing ionic liquids from primary alcohol-containing lignin compounds ADH1C, ADH5, ADH1A HRH3 3842/4885TSHR 4765/4885MAPK1 1991/4885
US-11034646-B2 Method for the synthesis of unsymmetrical tertiary amines ADH1C, PNMT, ADH1A HRH3 88/4885TSHR 1103/4885MAPK1 2759/4885
US-20070129351-A1 NOVEL PROCESSES FOR THE PREPARATION OF CYCLOPROPYL-AMIDE DERIVATIVES HRH4, HRH2, HRH1 HRH3 4/4885TSHR 375/4885MAPK1 3408/4885
US-20080113989-A1 For example, N-(1-Carbamoyl-1-oxo-3-phenylpropan-2-yl)-2-(E-2-(4-(1-pyrrolidinylmethyl)phenyl)ethen-1-yl)benzamide; calcium channel blockers; cardiovascular disorders; antiarthritic agents; inhibitors of enzymes, especially cysteine proteases such as calpain and cathepsins CAPN1, CAPNS1, CAPN2 HRH3 4432/4885TSHR 4029/4885MAPK1 1284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.